As a result, it was observed that the central members of the NF-κB pathway are more widely expressed in RS malignant cells than in CLL cells, mainly NFKB1 (RS: 27.5% vs. CLL: 6.7%, Figure 3A), NFKB2 (RS: 21.5% vs. CLL: 6.7%, Figure 3B), RELA (RS: 26.7% vs. CLL: 6.6%, Figure 3C), RELB (RS: 40.7% vs. CLL: 25.9%, Figure 3D), IKBKG (RS: 19.1% vs. CLL: 4.8%, Figure 3E), MAP3K14 (RS: 17.2% vs. CLL: 7.2%, Figure 3F), CHUK (RS: 5.8% vs. CLL: 1.7%, Figure 3G), and IKBKB (RS: 16.1% vs. CLL: 5.4%, Figure 3H). This evidence concerns the gene NFKB1 and B-cell chronic lymphocytic leukemia.